|
Figure 4.
Figure 4. Stereo representation of the BRCA1 -BARD1 RING domain
heterodimer depicting the locations of mutations found within
the BRCA1 (gray) and BARD1 (blue) RING domains8. Sites of
known cancer-predisposing mutations (C24R, C39S/Y, C44F, C47G/F,
C61G and C64G/R/Y) are shown in red. Sites of mutations found as
single occurrences in breast and ovarian cancer patients (R7C,
V11A, I15T, M18T, I21V, I31M, T37V, L52F, L63F, L87V, I89T and
I90T) are shown in black. Two Zn2+-liganding residues, Cys 27 in
site I and His 41 in site II (green), have not yet been
identified as mutations in cancer patients. No mutations within
the RING domain of BARD1 have yet been discovered in cancer
patients.
|
